drugset / Trial / NCT07228325

Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis

NCT07228325

Phase 1/2 Enrolling by invitation 50 enrolled Nasus Pharma
RandomizedSequentialOpen-labelTreatment

Summary

The study will evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) responses of FMXIN002, an intranasal epinephrine powder, compared with the EpiPen® intramuscular autoinjector, after single and double doses, in healthy adults with a history of allergic rhinitis.

Timeline

Start
2025-11-03
Primary completion
2026-03
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 0.3 mg Intramuscular
Subject FMXIN002 Unknown 4 mg Intranasal